Aug 12, 2020
Leading Biocatalysis and Biocatalyst Suppliers, 2019 - DuPont, Royal DSM, Codexis, BASF, AB Enzymes, Amano Enzymes, Novozymes, and Chr. Hansen - ResearchAndMarkets.com
Jun 15, 2020
FDA Grants Breakthrough Device Designation to Thermo Fisher Scientific's Oncomine Precision Assay to Identify IDH1 and IDH2 Mutations in Low-Grade Glioma Patients
Jun 12, 2020
Global Biocatalysis & Biocatalyst Market Trends, Forecast and Competitive Analysis to 2024 - ResearchAndMarkets.com
Jun 08, 2020
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
May 19, 2020
Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
May 11, 2020
The Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market is expected to grow by $ 810.23 million during 2020-2024 progressing at a CAGR of 12% during the forecast period
May 11, 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Apr 17, 2020
MedTest Dx Manufactures the Only FDA Approved Quantitative Test for G6PD, Critical when Considering COVID-19 Treatment with Chloroquine and Hydroxychloroquine
Apr 13, 2020
Ascletis Receives IND Approval for its HIV Drug ASC09F
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Mar 12, 2020
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease
Mar 09, 2020
UMD Researcher Establishes a New Viable CRISPR-Cas12b System for Plant Genome Engineering
Feb 10, 2020
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020
Feb 06, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Jan 30, 2020
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020
Jan 23, 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
Jan 14, 2020
Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Jan 09, 2020
Elysium Health(TM) Announces Clinical Trial to Study Correlations Between Epigenetic Aging and Nicotinamide Adenine Dinucleotide (NAD+) Levels in Healthy Adults
Jan 08, 2020
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)